Next Article in Journal
Age-Related Changes in Clinical and Analytical Variables in Chronic Hemodialyzed Patients
Previous Article in Journal
IFI16 Is Indispensable for Promoting HIF-1α-Mediated APOL1 Expression in Human Podocytes under Hypoxic Conditions
Previous Article in Special Issue
Bioactive Compounds and Their Influence on Postnatal Neurogenesis
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Editorial

The Effects of Bioactive Compounds on Human Brain Structures and Diseases

Department of Animal Physiology, Institute of Biology and Ecology, Faculty of Science, Pavol Jozef Safarik University, 041 54 Kosice, Slovakia
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2024, 25(6), 3326; https://doi.org/10.3390/ijms25063326
Submission received: 26 February 2024 / Revised: 13 March 2024 / Accepted: 14 March 2024 / Published: 15 March 2024
(This article belongs to the Special Issue Bioactive Compounds on Human Brain Structures and Diseases)
The human brain is the most intricate organ in the body. Throughout its development, environmental influences shape its trajectory, for better or for worse [1]. Because the brain is a vulnerable structure, it may be damaged during development, as well as during adulthood.
Brain diseases are the leading cause of disability-adjusted life years (DALYs) and the second leading cause of death [2,3]. Studies on complex neurodevelopmental disorders like schizophrenia and autism have revealed that a specific clinical syndrome can be linked to a diverse range of genetic risk factors. This implies the existence of multiple pathways from genetic makeup to observable behavior [4,5,6].
The aim of this Special Issue is to spotlight the mechanisms through which various bioactive compounds can promote neuroprotection in the brain and potentially prevent or treat brain diseases, such as neurodegenerative disorders, ischemic attacks, brain cancer, or depression.
Attention in the field of drug discovery has increasingly been focused on neuroprotection using natural compounds from traditional medicinal herbs [7]. According to the WHO, 80% of the global population relies on medicinal plant-based medicine to mitigate or cure diseases [8]. Plants are a source of pharmacologically potent drug molecules of high efficacy. Recently, herbal medicine has undergone rapid evolution, garnering globally acceptance owing to its natural origin [5]. Traditional medicines could represent an alternative option to allopathic treatments for curing various neurodegenerative disorders, because the latter are limited and can have severe adverse effects [9]. Natural products, secondary metabolites, and bioactive molecules derived from plants and microorganisms are key sources of bioactive molecules [10].
Herbal products contain complicated mixtures of organic chemicals, which may include fatty acids, sterols, alkaloids, flavonoids, glycosides, saponins, tannins, terpenes, etc. [11]. Metabolites such as tannins, anthocyanins, and alkaloids serve as a defense mechanism in live organisms and are undoubtedly compounds of interest in the food, cosmetic, and pharmaceutical industries [12].
Supporters of herbal medicines assert that the therapeutic value of plants arises from the synergistic effects of their various components, in contrast to the isolated chemicals identified by pharmacologists in conventional medicines. Consequently, traditional medicines are believed to be effective and have minimal or no side effects [11]. Bioactive compounds derived from plants have garnered significant attention because of their firmly established medicinal properties, including anti-apoptotic, antioxidant, anti-inflammatory, anticancer, antimicrobial, neuroprotective, hepatoprotective, and cardioprotective, properties [13].
Extracts from various plants are commonly used in traditional medicine, either alone or in combination [11]. Traditional Chinese medicine (TCM) is based on the balance between health and disease. Herbal medicines with memory-enhancing properties are also encompassed in TCM. The plants used in TCM for memory improvement include Huperzia serrata, Alpinia oxyphylla, Ginkgo biloba, Panax ginseng, Tripterygium wilfordii, Ganoderma lucidum, Camellia sinensis, Astragalus membranaceus, Polygonum multiflorum, Acanthopanax senticosus, Achyranthes bidentata, and many others [7,14,15].
The wealth of new studies in this field underscores the undeniable potential of natural compounds and herbal mixtures, underscoring their crucial roles in molecular neuroprotective mechanisms. These findings may pave the way for the development of protective agents derived from traditional herbal medicine for addressing neurodegenerative and neurological disorders.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Tost, H.; Champagne, F.A.; Meyer-Lindenberg, A. Environmental influence in the brain, human welfare and mental health. Nat. Neurosci. 2015, 18, 1421–1431. [Google Scholar] [CrossRef] [PubMed]
  2. Feigin, V.L.; Vos, T.; Nichols, E.; Owolabi, M.O.; Carroll, W.M.; Dichgans, M.; Deuschl, G.; Parmar, P.; Brainin, M.; Murray, C. The global burden of neurological disorders: Translating evidence into policy. Lancet Neurol. 2020, 19, 255–265. [Google Scholar] [CrossRef] [PubMed]
  3. GBD. Global, regional, and national burden of neurological disorders, 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019, 18, 459–480. [Google Scholar] [CrossRef] [PubMed]
  4. Abrahams, B.S.; Geschwind, D.H. Advances in autism genetics: On the threshold of a new neurobiology. Nat. Rev. Genet. 2008, 9, 341–355. [Google Scholar] [CrossRef] [PubMed]
  5. Halder, S.; Anand, U.; Nandy, S.; Oleksak, P.; Qusti, S.; Alshammari, E.M.; El-Saber Batiha, G.; Koshy, E.P.; Dey, A. Herbal drugs and natural bioactive products as potential therapeutics: A review on pro-cognitives and brain boosters perspectives. Saudi Pharm. J. 2021, 29, 879–907. [Google Scholar] [CrossRef] [PubMed]
  6. Walsh, T.; McClellan, J.M.; McCarthy, S.E.; Addington, A.M.; Pierce, S.B.; Cooper, G.M.; Nord, A.S.; Kusenda, M.; Malhotra, D.; Bhandari, A.; et al. Rare Structural Variants Disrupt Multiple Genes in Neurodevelopmental Pathways in Schizophrenia. Science 2008, 320, 539–543. [Google Scholar] [CrossRef] [PubMed]
  7. Wu, P.-f.; Zhang, Z.; Wang, F.; Chen, J.-g. Natural compounds from traditional medicinal herbs in the treatment of cerebral ischemia/reperfusion injury. Acta Pharmacol. Sin. 2010, 31, 1523–1531. [Google Scholar] [CrossRef] [PubMed]
  8. Malaquias, G.; Cerqueira, G.; Ferreira, P.; Pacheco, A.; Sousa, J.; Deus, M.; Peron, A. Utilização na medicina popular, potencial terapêutico e toxicidade em nível celular das plantas Rosmarinus officinalis L., Salvia officinalis L. e Mentha piperita L. (Família Lamiaceae). RevInter Rev. Intertox Toxicol. Risco Ambient. Soc. 2014, 7, 50–68. [Google Scholar] [CrossRef]
  9. Puri, V.; Kanojia, N.; Sharma, A.; Huanbutta, K.; Dheer, D.; Sangnim, T. Natural product-based pharmacological studies for neurological disorders. Front. Pharmacol. 2022, 13, 1011740. [Google Scholar] [CrossRef] [PubMed]
  10. Ratcliffe, C.; Wandschneider, B.; Baxendale, S.; Thompson, P.; Koepp, M.J.; Caciagli, L. Cognitive Function in Genetic Generalized Epilepsies: Insights From Neuropsychology and Neuroimaging. Front. Neurol. 2020, 11, 144. [Google Scholar] [CrossRef] [PubMed]
  11. Kumar, G.P.; Khanum, F. Neuroprotective potential of phytochemicals. Pharmacogn. Rev. 2012, 6, 81–90. [Google Scholar] [CrossRef] [PubMed]
  12. Barba-Ostria, C.; Carrera-Pacheco, S.E.; Gonzalez-Pastor, R.; Heredia-Moya, J.; Mayorga-Ramos, A.; Rodríguez-Pólit, C.; Zúñiga-Miranda, J.; Arias-Almeida, B.; Guamán, L.P. Evaluation of Biological Activity of Natural Compounds: Current Trends and Methods. Molecules 2022, 27, 4490. [Google Scholar] [CrossRef] [PubMed]
  13. Shoaib, S.; Ansari, M.A.; Fatease, A.A.; Safhi, A.Y.; Hani, U.; Jahan, R.; Alomary, M.N.; Ansari, M.N.; Ahmed, N.; Wahab, S.; et al. Plant-Derived Bioactive Compounds in the Management of Neurodegenerative Disorders: Challenges, Future Directions and Molecular Mechanisms Involved in Neuroprotection. Pharmaceutics 2023, 15, 749. [Google Scholar] [CrossRef] [PubMed]
  14. Yan, H.; Li, L.; Tang, X.C. Treating senile dementia with traditional Chinese medicine. Clin. Interv. Aging 2007, 2, 201–208. [Google Scholar] [PubMed]
  15. Zhang, Z.; Zhang, S.; Lui, C.N.-P.; Zhu, P.; Zhang, Z.; Lin, K.; Dai, Y.; Yung, K.K.-L. Traditional Chinese medicine-based neurorestorative therapy for Alzheimer’s and Parkinson’s disease. J. Neurorestoratol. 2019, 7, 207–222. [Google Scholar] [CrossRef]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Kiskova, T.; Smajda, B. The Effects of Bioactive Compounds on Human Brain Structures and Diseases. Int. J. Mol. Sci. 2024, 25, 3326. https://doi.org/10.3390/ijms25063326

AMA Style

Kiskova T, Smajda B. The Effects of Bioactive Compounds on Human Brain Structures and Diseases. International Journal of Molecular Sciences. 2024; 25(6):3326. https://doi.org/10.3390/ijms25063326

Chicago/Turabian Style

Kiskova, Terezia, and Benadik Smajda. 2024. "The Effects of Bioactive Compounds on Human Brain Structures and Diseases" International Journal of Molecular Sciences 25, no. 6: 3326. https://doi.org/10.3390/ijms25063326

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop